Homeostatic Roles of Eosinophils in Asthma
ConditionAsthma; Eosinophilic
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Besancon
About this trial
The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma
Signature of informed consent
Affiliation with the French social security system
Disqualifiers
Non-eosinophilic asthma
Coexistence of a chronic eosinophilic inflammatory condition other than asthma
Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.)
Treatment with corticosteroids within 10 days prior to inclusion
Trial design
Design model
Single group
Treatments tested in this trial
Blood Punction
Procedure/Surgeryvenous blood sampling
Treatment groups
100 Participants
are divided into 5 treatment groupsGroup A: Severe Asthma Patients : Biologic NaïvesOther 1 intervention
Group B: Severe Asthma Patients: Responders to BiologicsOther 1 intervention
Group C: Severe Asthma Patients: Non Responders to BiologicsOther 1 intervention
Group D: Mild asthmaticsOther 1 intervention
Group E: Healthy ControlsOther 1 intervention
Trial outcomes
Primary outcomes
1
Flow cytometry based eosinophil phenotyping : Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)
Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)
Time frame
at inclusionLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: